# Catalysis SL clinical trials: 53 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 53 trials with Catalysis SL as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Catalysis SL: 53 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/catalysis-sl

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 53
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 53, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 17, 2025 | NCT07179237 | Efficacy of Carminal in Helicobacter Pylori Gastritis | Catalysis SL | Phase 2 | Recruiting | H Pylori Gastritis, H Pylori Infection, H Pylori Eradication, Gastritis Associated With Helicobacter Pylori, Gastric... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179237) |
| July 11, 2024 | NCT06496087 | Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment | Catalysis SL | Not applicable | Completed | Depression, Post-COVID-19 Syndrome, Depression Mild, Depression Moderate | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06496087) |
| May 31, 2024 | NCT06437210 | Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome | Catalysis SL | Not applicable | Completed | Post-COVID-19 Syndrome, COVID-19, Dyspnea, Fatigue, Cough, Inflammation | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06437210) |
| April 12, 2024 | NCT06363201 | Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours | Catalysis SL | Not applicable | Unknown | Advanced Cancer, Advanced Solid Tumor, Lymphoma, Hodgkin, Central Nervous System Tumor, Sarcoma, Germ Cell Tumor... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06363201) |
| April 12, 2024 | NCT06361992 | Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children | Catalysis SL | Phase 3 | Completed | Atopic Dermatitis, Atopic Dermatitis and Related Conditions, Atopic Dermatitis Eczema, Atopic Dermatitis \\(AD\\) | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06361992) |
| June 23, 2023 | NCT05916911 | Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With... | Catalysis SL | Phase 4 | Unknown | Papilloma Viral Infection, CIN1, LSIL, Low Grade Squamous Intraepithelial Lesion | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05916911) |
| February 3, 2022 | NCT05222841 | The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility | Catalysis SL | Phase 2/3 | Completed | Male Infertility, Benign Prostatic Hyperplasia, Spermatogenesis and Semen Disorders | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05222841) |
| July 28, 2021 | NCT04980534 | Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip | Catalysis SL | Not applicable | Completed | Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, Viral Infection, Respiratory Tract Infections, Infection... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04980534) |
| January 8, 2021 | NCT04701502 | Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19 | Catalysis SL | Phase 2 | Completed | Covid19, Respiratory Disease, Immune System, Immunomodulator, Antiseptic, Supportive Care | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04701502) |
| January 6, 2021 | NCT04695951 | Efficacy and Safety of Renalof® in the Removal of Calculi Smaller Than 10 mm Located in the Reno-Ureteral Tract | Catalysis SL | Phase 2 | Completed | Renal Injury, Kidney Injury, Kidney Calculi, Ureteral Obstruction, Ureteral Calculi, Renal Stone, Ureteral Injury... | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04695951) |
| May 29, 2020 | NCT04407182 | Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 | Catalysis SL | Phase 2 | Completed | Covid-19, Sars-CoV2, Diabete Mellitus, Cardiopathy, Pulmonary Disease, Renal Disease, Liver Diseases | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04407182) |
| October 24, 2018 | NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | Catalysis SL | Phase 2 | Completed | Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03717298) |
| July 12, 2018 | NCT03584308 | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | Catalysis SL | Phase 2 | Completed | Papilloma Viral Infection, Papillomavirus Infections, Esophageal Viral Wart, Esophageal Verrucous Carcinoma | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03584308) |
| July 11, 2018 | NCT03583593 | Evaluation of DIAMEL® Combined With Insulin in Diabetic Foot Ulcer | Catalysis SL | Phase 2 | Completed | Diabetic Foot Ulcer, Diabetic Foot, Diabetes Mellitus, Type 2 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03583593) |
| July 5, 2018 | NCT03577535 | Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients. | Catalysis SL | Phase 2 | Completed | Mucositis Oral | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03577535) |
| July 3, 2018 | NCT03576521 | Evaluation of Ocoxin®-Viusid® in Breast Cancer | Catalysis SL | Phase 2 | Completed | Breast Cancer, Breast Carcinoma, Adriamycin Toxicity, Cyclosporine Toxicity | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03576521) |
| June 20, 2018 | NCT03562897 | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | Catalysis SL | Phase 2 | Completed | Carcinoma, Ovarian Neoplasm, Endocrine Gland Neoplasm, Urogenital Neoplasms, Ovarian Diseases, Adnexal Diseases... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03562897) |
| June 18, 2018 | NCT03559543 | Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma | Catalysis SL | Phase 2 | Completed | Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Rectal Diseases... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03559543) |
| June 8, 2018 | NCT03550482 | Oncoxin® and Quality of Life in Cancer Patients | Catalysis SL | Phase 4 | Completed | Gastric Cancer Stage II, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, Gastric Cancer... | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03550482) |
| June 8, 2018 | NCT03549494 | Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction | Catalysis SL | Phase 2 | Completed | Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Esophageal Neoplasms, Head and Neck Neoplasms... | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03549494) |
| June 7, 2018 | NCT03549273 | Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions | Catalysis SL | Phase 2 | Unknown | Carcinoma, Neoplasia; Intraepithelial, Cervix, Glandular Neoplasms, Epithelial Neoplasm, Neoplasms | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03549273) |
| June 1, 2018 | NCT03543670 | Evaluation of Oncoxin-Viusid® in Prostate Cancer | Catalysis SL | Phase 2 | Completed | Prostate Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03543670) |
| May 31, 2018 | NCT03541772 | Evaluation of Oncoxin-Viusid® in Head and Neck Cancer | Catalysis SL | Phase 2 | Completed | Head Cancer Neck | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03541772) |
| May 30, 2018 | NCT03541148 | Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma | Catalysis SL | Phase 2 | Completed | Cutaneous Melanoma, Stage II, Malignant Cutaneous Melanoma, Cutaneous Melanoma, Stage III | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03541148) |
| May 30, 2018 | NCT03541005 | Evaluation of Obex® in Overweight and Obesity | Catalysis SL | Phase 3 | Completed | Overweight and Obesity | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03541005) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 21 |
| Phase 2/3 | 3 |
| Phase 3 | 23 |
| Phase 4 | 2 |
| Not applicable | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 48 |
| Unknown | 3 |
| Recruiting | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 4 |
| Overweight | 3 |
| Obesity | 3 |
| Insulin Resistance | 3 |
| Weight Loss | 3 |
| Digestive System Neoplasms | 3 |
| Digestive System Diseases | 3 |
| Diabetes Mellitus | 3 |
| Hepatitis C, Chronic | 2 |
| Carcinoma | 2 |
| Endocrine Gland Neoplasms | 2 |
| Endocrine System Diseases | 2 |
| Neoplasms, Glandular and Epithelial | 2 |
| Papillomavirus Infections | 2 |
| Infertility, Male | 2 |
| Stomach Neoplasms | 2 |
| Neoplasms | 2 |
| Kidney Calculi | 2 |
| Kidney Diseases | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Motor Activity | 2 |
| Gastrointestinal Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Gastrointestinal Diseases | 2 |
| Depression | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B transportation and storage companies in the United States](https://specstream.ai/data/businesses/b2b-transportation-and-storage-companies/united-states)
- [Telecommunications services in the United States](https://specstream.ai/data/businesses/telecommunications-services/united-states)
- [Patent law firms in the United States](https://specstream.ai/data/businesses/patent-law-firms/united-states)
- [Hospices in the United States](https://specstream.ai/data/businesses/hospices/united-states)
- [Crane services in the United States](https://specstream.ai/data/businesses/crane-services/united-states)
- [Art restoration companies in the United States](https://specstream.ai/data/businesses/art-restoration-companies/united-states)
